PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges
Keywords: PCSK9 inhibitors; Statins; Lipid lowering therapies; LDL-C; Low-density lipoprotein cholesterol; LDL-R; Low-density lipoprotein receptor; PCSK9; Proprotein Convertase Subtilisin/Kexin type 9; ACS; Acute coronary syndrome; FDA; Food and Drug Administration